BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures
M.S.Q. Ventures (“MSQ”) is pleased to announce that its client, BioLineRx Ltd. (“BioLineRx”) (NASDAQ/TASE: BLRX), has entered into an exclusive license agreement with Guangzhou Gloria Biosciences Co., Ltd. (GloriaBio) and an associated investor for the development of motixafortide across all indications in Asia. The license agreement provides for a $15 million upfront payment and an equity investment of $14.6 million, up…